Trial 1B-19-2


Elacestrant Monotherapy vs Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active Controlled, Multicenter Trial (EMERALD)

Type: Treatment
Phase: Phase III
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Chemotherapy: Systemic
Randomized: No
USC Satellite Location: USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Darcy Spicer, M.D.
Other Trial Staff:  Lusine Raddatz, D.M., Grace Facio, R.N., Marissa Aldana, D.M., Margarita Carranza, D.M., America Casillas-Lopez, Coordinator, Apoorva Vishwanath, D.M., Brigitte Torres, Coordinator, Sophie Miehl, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.